Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > COLUMN
COLUMN
- It’s Your Choice
December 18, 2015
- Ask a Question and Shut Up
November 27, 2015
- Recruiternomics
October 30, 2015
- Pharma Companies in JPAC Are Searching for the Goldilocks Candidate
September 25, 2015
- No… Your Company Is Not like a Family!
August 28, 2015
- What’s Your Pharma Company’s Brand in Japan?
July 24, 2015
- Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
- Current Topics of New Drug Development and Marketing in the World: 1
July 9, 2015
- The Mastery of Recruitment
June 26, 2015
- “Every Search Is Won Before It’s Ever Fought”: Sun Tzu
May 22, 2015
- The Truth about Recruiters
April 21, 2015
- When Interviewing, Share the Love
March 27, 2015
- Sales Experience for Marketers Deceasing in Japan’s Pharma Industry
February 20, 2015
- Eliminating Bias from the Interview Process
January 23, 2015
- Loss Aversion: Why Candidates Reject Offers
December 26, 2014
- What You Don’t Know About Communication Can Hurt You
November 28, 2014
- 3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
- Successful People Have the Best Information
September 24, 2014
- Is Your Body Language Louder than Your Speech?
August 25, 2014
- Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…